6 September 2010, 3:04 am
"- - " ThromboGenics NV , a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA Congress in Paris, France.... Read More »